Literature DB >> 34453120

Steatosis, inflammasome upregulation, and fibrosis are attenuated in miR-155 deficient mice in a high fat-cholesterol-sugar diet-induced model of NASH.

Shashi Bala1, Michal Ganz2, Mrigya Babuta1, Yuan Zhuang1, Timea Csak2, Charles D Calenda1, Gyongyi Szabo3.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease globally. miRNAs (miRs) regulate various cellular events that lead to NAFLD. In this study we tested the hypothesis that miR-155 is an important regulator of steatohepatitis and fibrosis pathways. Wild type (WT) or miR-155 deficient (KO) mice received a high fat-high cholesterol-high sugar-diet (HF-HC-HS) for 34 weeks and liver tissues were analyzed. In patients with nonalcoholic steatohepatitis and in the mouse model of HF-HC-HS diet we found increased miR-155 levels in the liver compared to normal livers. Upon HF-HC-HS diet feeding, miR-155 KO mice displayed less liver injury, decreased steatosis, and attenuation in fibrosis compared to WT mice. ALT, triglyceride levels, and genes involved in fatty acid metabolic pathway were increased in WT mice whereas miR-155 KO mice showed attenuation in these parameters. HF-HC-HS diet-induced significant increase in the expression of NLRP3 inflammasome components in the livers of WT mice compared to chow fed diet. Compared to WT mice, miR-155 KO showed attenuated induction in the NLRP3, ASC, and caspase1 inflammasome expression on HF-HC-HS diet. Fibrosis markers such as collagen content and deposition, αSMA, Zeb2, and vimentin were all increased in WT mice and miR-155 KO mice showed attenuated fibrosis marker expression. Overall, our findings highlight a role for miR-155 in HF-HC-HS diet-induced steatosis and liver fibrosis.
© 2021. The Author(s), under exclusive licence to United States and Canadian Academy of Pathology.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34453120      PMCID: PMC9272486          DOI: 10.1038/s41374-021-00626-1

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.502


  39 in total

Review 1.  Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics.

Authors:  Stergios A Polyzos; Jannis Kountouras; Christos S Mantzoros
Journal:  Metabolism       Date:  2018-11-29       Impact factor: 8.694

2.  MicroRNA-155 targets SMAD2 and modulates the response of macrophages to transforming growth factor-{beta}.

Authors:  Fethi Louafi; Rocio T Martinez-Nunez; Tilman Sanchez-Elsner
Journal:  J Biol Chem       Date:  2010-10-29       Impact factor: 5.157

Review 3.  MicroRNA-155: A Master Regulator of Inflammation.

Authors:  Guruswamy Mahesh; Roopa Biswas
Journal:  J Interferon Cytokine Res       Date:  2019-03-20       Impact factor: 2.607

4.  Decreased MiR-155 Level in the Peripheral Blood of Non-Alcoholic Fatty Liver Disease Patients may Serve as a Biomarker and may Influence LXR Activity.

Authors:  Lei Wang; Ning Zhang; Zun Wang; Dong-Mei Ai; Zhen-Yu Cao; Hua-Ping Pan
Journal:  Cell Physiol Biochem       Date:  2016-11-07

5.  Silencing of miR‑155 suppresses inflammatory responses in psoriasis through inflammasome NLRP3 regulation.

Authors:  Quan Luo; Jingxin Zeng; Wei Li; Ling Lin; Xin Zhou; Xin Tian; Weiyu Liu; Lidan Zhang; Xibao Zhang
Journal:  Int J Mol Med       Date:  2018-05-14       Impact factor: 4.101

Review 6.  The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD).

Authors:  Elena Buzzetti; Massimo Pinzani; Emmanuel A Tsochatzis
Journal:  Metabolism       Date:  2016-01-04       Impact factor: 8.694

Review 7.  Molecular pathways in non-alcoholic fatty liver disease.

Authors:  Alba Berlanga; Esther Guiu-Jurado; José Antonio Porras; Teresa Auguet
Journal:  Clin Exp Gastroenterol       Date:  2014-07-05

8.  MicroRNA-155 regulates monocyte chemokine and chemokine receptor expression in Rheumatoid Arthritis.

Authors:  Aziza Elmesmari; Alasdair R Fraser; Claire Wood; Derek Gilchrist; Diane Vaughan; Lynn Stewart; Charles McSharry; Iain B McInnes; Mariola Kurowska-Stolarska
Journal:  Rheumatology (Oxford)       Date:  2016-07-13       Impact factor: 7.580

Review 9.  The Role of NLRP3 Inflammasome Activation in the Epithelial to Mesenchymal Transition Process During the Fibrosis.

Authors:  Amani Abraheem Alsadiq Alyaseer; Murilo Henrique Saturnino de Lima; Tarcio Teodoro Braga
Journal:  Front Immunol       Date:  2020-05-20       Impact factor: 7.561

10.  MicroRNA-155-5p suppresses the migration and invasion of lung adenocarcinoma A549 cells by targeting Smad2.

Authors:  Jianfeng Lin; Youqin Chen; Liya Liu; Aling Shen; Wei Zheng
Journal:  Oncol Lett       Date:  2018-06-04       Impact factor: 2.967

View more
  5 in total

1.  Influence of dietary sodium taurocholate on the growth performance and liver health of Nile tilapia (Oreochromis niloticus).

Authors:  Fei-Fei Ding; Miao Li; Tong Wang; Nan-Nan Zhou; Fang Qiao; Zhen-Yu Du; Mei-Ling Zhang
Journal:  Fish Physiol Biochem       Date:  2022-08-31       Impact factor: 3.014

2.  Ganoderic acid A ameliorates non-alcoholic streatohepatitis (NASH) induced by high-fat high-cholesterol diet in mice.

Authors:  Jing Zhu; Jiexia Ding; Siying Li; Jie Jin
Journal:  Exp Ther Med       Date:  2022-02-24       Impact factor: 2.447

3.  Circulating microRNAs Are Associated With Metabolic Markers in Adolescents With Hepatosteatosis.

Authors:  Haixia Lin; Kelly E Mercer; Xiawei Ou; Kori Mansfield; Robert Buchmann; Elisabet Børsheim; Emir Tas
Journal:  Front Endocrinol (Lausanne)       Date:  2022-04-14       Impact factor: 6.055

Review 4.  Noncoding RNAs as additional mediators of epigenetic regulation in nonalcoholic fatty liver disease.

Authors:  Mohamed Zaiou
Journal:  World J Gastroenterol       Date:  2022-09-21       Impact factor: 5.374

Review 5.  Diet and Gut Microbiota Interaction-Derived Metabolites and Intrahepatic Immune Response in NAFLD Development and Treatment.

Authors:  Ming Yang; Lea Khoukaz; Xiaoqiang Qi; Eric T Kimchi; Kevin F Staveley-O'Carroll; Guangfu Li
Journal:  Biomedicines       Date:  2021-12-13
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.